PEDIATRICS Vol. 82 No. 5 November 1988, pp. 756-762
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kendig, J. W.
Right arrow Articles by Shapiro, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kendig, J. W.
Right arrow Articles by Shapiro, D. L.

Surfactant Replacement Therapy at Birth: Final Analysis of a Clinical Trial and Comparisons With Similar Trials

James W. Kendig MD1, Robert H. Notter MD, PhD1, Christopher Cox PhD1, Judy L. Aschner MD1, Steven Benn MD1, Richard M. Bernstein MD1, Karen Hendricks-Munoz MD1, William M. Maniscalco MD1, Leon A. Metlay MD1, Dale L. Phelps MD1, Robert A. Sinkin MD1, Beverly P. Wood MD1, and Donald L. Shapiro MD1

1 From the Departments of Pediatrics (Neonatology), Radiology, Pathology, and Laboratory Medicine, the Division of Biostatistics, and the Specialized Center of Research in Pulmonary Diseases of Newborns, University of Rochester School of Medicine and Dentistry, Rochester, New York

A randomized trial of surfactant replacement therapy at birth was conducted at the University of Rochester between June 1983 and November 1985. Thirty-four premature infants, 25 to 29 weeks' gestational age, received a preventilatory dose of a calf lung surfactant extract in saline prepared at the University of Rochester. A control group of 31 infants received a preventilatory dose of saline alone. The major finding of this trial is that a single preventilatory dose of calf lung surfactant extract reduces the severity of the respiratory distress syndrome during the first 24 hours of life. The beneficial effects, however, are not sustained in many infants and diminish after 24 hours of life. The survival rate was 71% in both the control and surfactant-treated groups. There was a lower incidence of pneumothorax in the surfactant-treated group. There were no differences in the incidence of bronchopulmonary dysplasia, patent ductus arteriosus, and intraventricular hemorrhage. No adverse effects of surfactant replacement therapy were identified. Results of this study suggest that multiple postventilatory doses of surfactant will be required for optimal therapy.

Key Words: surfactant replacement therapy • respiratory distress syndrome • lung • premature infants

Submitted on January 11, 1988
Accepted on April 18, 1988




This article has been cited by other articles:


Home page
 PediatricsHome page
C. T. D'Angio, R. A. Sinkin, T. P. Stevens, N. K. Landfish, J. L. Merzbach, R. M. Ryan, D. L. Phelps, D. R. Palumbo, and G. J. Myers
Longitudinal, 15-Year Follow-up of Children Born at Less Than 29 Weeks' Gestation After Introduction of Surfactant Therapy Into a Region: Neurologic, Cognitive, and Educational Outcomes
Pediatrics, December 1, 2002; 110(6): 1094 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
T. Bhuta and A. Ohlsson
Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 1998; 79(1): 26F - 33.
[Abstract] [Full Text]

Home page
 NEJMHome page
A. H. Jobe
Pulmonary Surfactant Therapy
N. Engl. J. Med., March 25, 1993; 328(12): 861 - 868.
[Full Text]

Home page
 JWatch GeneralHome page
SURFACTANT-REPLACEMENT THERAPY FOR NEONATAL RESPIRATORY DISTRESS SYNDROME
Journal Watch (General), November 25, 1988; 1988(1125): 4 - 4.
[Full Text]